Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019

Jeremy A W Gold; Seda S Tolu; Tom Chiller; Kaitlin Benedict; Brendan R Jackson

doi:10.1093/cid/ciab1026

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019

Clin Infect Dis. 2022 Aug 25;75(2):334-337. doi: 10.1093/cid/ciab1026.

Authors

Jeremy A W Gold¹, Seda S Tolu², Tom Chiller¹, Kaitlin Benedict¹, Brendan R Jackson¹

Affiliations

¹ Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.

Abstract

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).

Keywords: cancer; ibrutinib; invasive fungal infections; opportunistic infections; small molecule kinase inhibitors.

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

MeSH terms

Adenine* / adverse effects
Adenine* / analogs & derivatives
Humans
Incidence
Invasive Fungal Infections* / drug therapy
Invasive Fungal Infections* / epidemiology
Piperidines*
United States / epidemiology

Substances

Piperidines
ibrutinib
Adenine

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States